Socio-demographic and clinical characteristics
| Item | ApoE4 (N=11) | Controls (N=40) | p |
|---|---|---|---|
| Gender (Female) | 7 (63.6%) | 34 (85%) | .193 |
| Age | 65.64 (8.02) | 64.75 (7.19) | .725 |
| Education (years) – Mean (SD) | 13.18 (3.49) | 13 (3.20) | |
| Median (IQR) | 13 (12-16) | 13 (10.25-16) | .872 |
| From Urban areas | 7 (63.6) | 24 (60) | .827 |
| In a relationship | 5 (45.5) | 22 (55) | .574 |
| BMI – Mean (SD) | 27.98 (5.08) | 28.66 (4.61) | |
| Median (IQR) | 25.71 (23.44-34.24) | 27.82 (25.31-31.82) | .544 |
| Hypertension | 8 (72.7) | 26 (65) | .731 |
| Type II Diabetes | 1 (9.1) | 8 (20) | .663 |
| Currently pharmacological treatment for somatic disorders | 8 (72.7) | 34 (85) | .385 |
| History of Psychiatric disorders | 5 (45.5) | 10 (25) | .187 |
| HAM-D score, Mean (SD) | 2 (2.28) | 2.2 (1.59) | |
| Median (IQR) | 1 (0-3) | 2 (1-3) | .393 |
| HAM-A score, Mean (SD) | 2.64 (2.34) | 2.95 (2.14) | |
| Median (IQR) | 2 (0-4) | 2 (2-4) | .699 |
Cognitive evaluation of ApoE4 positives vs controls
| Item | ApoE4 positive (N=11) | Controls (N=40) | p |
|---|---|---|---|
| MMSE | |||
| Mean (SD) | 28.46 (1.81) | 28.35 (1.33) | |
| Median (IQR) | 29 (27-30) | 28 (27-29.75) | .553 |
| RAVLT Trial 1 | |||
| Mean (SD) | 3.82 (1.54) | 4.35 (1.73) | |
| Median (IQR) | 4 (3-5) | 4 (3-5) | .342 |
| RAVLT Trial 5 | 8 (3.07) | 9.63 (2.73) | .095 |
| RAVLT Total | 31.36 (9.85) | 37.28 (10.52) | .101 |
| RAVLT Trial 6 | 6.64 (2.46) | 7.73 (3.40) | .328 |
| RAVLT Delay | 5.82 (3.34) | 7.25 (3.5) | .231 |
| RAVLT Recognition | |||
| Mean (SD) | 10.82 (3.71) | 13.18 (2.49) | |
| Median (IQR) | 10 (7-15) | 14 (12.25-15) | .085 |
| Rey Copying | |||
| Mean (SD) | 31.32 (8.10) | 32.54 (6.27) | |
| Median (IQR) | 34 (32-35) | 35 (32-36) | .275 |
| Rey Memory | 12.32 (8.95) | 18.7 (7.39) | .019 |
| TMT A | |||
| Mean (SD) | 107.55 (117.1) | 70.85 (48.04) | |
| Median (IQR) | 63 (46-113) | 57 (43.25-85.25) | .261 |
| TMT B | |||
| Mean (SD) | 232 (205.77) | 164.65 (90.26) | |
| Median (IQR) | 98 (85-480) | 142 (102.75-204.75) | .828 |
| VFT Total | 27 (10.33) | 28 (10.42) | .779 |